| First Author | Di Luccia B | Year | 2019 |
| Journal | J Exp Med | Volume | 216 |
| Issue | 10 | Pages | 2231-2241 |
| PubMed ID | 31296736 | Mgi Jnum | J:359134 |
| Mgi Id | MGI:6364483 | Doi | 10.1084/jem.20180549 |
| Citation | Di Luccia B, et al. (2019) ILC3s integrate glycolysis and mitochondrial production of reactive oxygen species to fulfill activation demands. J Exp Med 216(10):2231-2241 |
| abstractText | Group 3 innate lymphoid cells (ILC3s) are the innate counterparts of Th17 that require the transcription factor RORgammat for development and contribute to the defense against pathogens through IL-22 and IL-17 secretion. Proliferation and effector functions of Th17 require a specific mTOR-dependent metabolic program that utilizes high-rate glycolysis, while mitochondrial lipid oxidation and production of reactive oxygen species (mROS) support alternative T reg cell differentiation. Whether ILC3s employ a specific metabolic program is not known. Here, we find that ILC3s rely on mTOR complex 1 (mTORC1) for proliferation and production of IL-22 and IL-17A after in vitro activation and Citrobacter rodentium infection. mTORC1 induces activation of HIF1alpha, which reprograms ILC3 metabolism toward glycolysis and sustained expression of RORgammat. However, in contrast to Th17, ILC3 activation requires mROS production; rather than inducing an alternative regulatory fate as it does in CD4 T cells, mROS stabilizes HIF1alpha and RORgammat in ILC3s and thereby promotes their activation. We conclude that ILC3 activation relies on a metabolic program that integrates glycolysis with mROS production. |
